$233.94 -$1.66 (-0.7%)

04:30 PM EST on 01/24/20

DexCom, Inc. (NASDAQ:DXCM)

CAPS Rating: 4 out of 5

A medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for people with diabetes.

Current Price $233.94 Mkt Cap $21.4B
Open $237.77 P/E Ratio 0.00
Prev. Close $233.94 Div. (Yield) $0.00 (0.0%)
Daily Range $233.09 - $238.70 Volume 533,822
52-Wk Range $213.69 - $242.14 Avg. Daily Vol. 830,856

Caps

How do you think NASDAQ:DXCM will perform against the market?

Add Stock to CAPS Watchlist

All Players

136 Outperform
90 Underperform
 

All-Star Players

36 Outperform
18 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:DXCM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (88.05)
Submitted June 14, 2018

Its platform agnostic blood glucose monitor is a component in both Insulet and Tandem Diabetes closed-loop (artificial pancreas) solution and efforts to pair up DexCom's CGMs with other insulin systems, including smart pens, suggests the company will… More

BiLoandWise (22.18)
Submitted May 04, 2008

Their devices haven't been selling, their financials are awful, the stock price has been plummeting and they're headed toward bankruptcy.

Recent Community Commentary

Read the most recent pitches from players about DXCM.

Recs

0
Member Avatar wrciii (42.81) Submitted: 1/15/2020 8:32:01 PM : Outperform Start Price: $235.44 NASDAQ:DXCM Score: -0.39

Diabetes epidemic

Recs

0
Member Avatar CrotalusJoe (< 20) Submitted: 2/13/2019 9:28:48 PM : Outperform Start Price: $148.30 NASDAQ:DXCM Score: +37.64

Increasing obesity/diabetes rates = need for their product

Recs

0
Member Avatar TMFProcess (81.82) Submitted: 1/12/2019 3:59:15 PM : Outperform Start Price: $140.43 NASDAQ:DXCM Score: +38.57

Top dog in CGM space with multiple partnerships with pump providers with innovative technology. Most accurate CGM available with a focus on ease of use through smartphone integration. G6 no-calibration product is still growing and its Verily product in partnership with Alphabet is coming to market soon(?) In a growing diabetes market, Dexcom is positioned to outperform

Leaderboard

Find the members with the highest scoring picks in DXCM.

Score Leader

ardys13

ardys13 (< 20) Score: +5,939.45

The Score Leader is the player with the highest score across all their picks in DXCM.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
ardys13 < 20 2/9/2009 Outperform 1Y $3.70 +6,222.70% +283.26% +5,939.45 1 Comment
bigrick22 89.60 3/24/2008 Outperform NS $4.00 +5,748.50% +155.79% +5,592.71 0 Comment
CleverKat 60.98 3/24/2008 Outperform NS $4.27 +5,378.69% +153.00% +5,225.69 0 Comment
MEGIN7790 < 20 4/4/2008 Outperform NS $4.45 +5,157.08% +148.15% +5,008.93 0 Comment
cpalerm 90.54 3/23/2009 3/13/2014 Outperform 5Y $4.32 +5,315.28% +321.96% +4,993.31 1 Comment
LazyTimeMoney 68.58 4/7/2008 Outperform NS $5.04 +4,541.67% +147.73% +4,393.94 0 Comment
jabrink 77.24 4/7/2008 Outperform 3W $5.07 +4,514.20% +147.53% +4,366.67 0 Comment
GriffinRex 84.86 4/8/2008 Outperform 3M $5.17 +4,424.95% +150.30% +4,274.65 0 Comment
cash4metoo 57.69 5/28/2009 Outperform 1Y $5.34 +4,280.90% +267.30% +4,013.60 0 Comment
YahooSIRIous 74.37 7/13/2009 Outperform 5Y $5.35 +4,272.71% +274.13% +3,998.58 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DXCM.